The Foundation for Angelman Syndrome Therapeutics to Contribute Data to C-Path’s RDCA-DAP, Accelerating Neurological Disease Research and Therapeutic Development

TUCSON, Ariz., July 19, 2023 — Critical Path Institute (C-Path) announced today that the Foundation for Angelman Syndrome Therapeutics (FAST), a nonprofit organization dedicated to finding a cure for this genetic disorder, have contributed data from the Global Angelman Syndrome Registry to the Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP®), managed by C-Path.Continue reading

Aqualung Therapeutics Receives FDA Clearance To Proceed With the P2A PUERTA Study in Moderate/Severe Acute Respiratory Distress Syndrome (ARDS) Patients

  • Aqualung Therapeutics will initiate moderate/severe ARDS patient recruitment for U.S. and Australia hospital sites in August 2023.
  • Aqualung appoints Jackson Streeter MD to their board of directors bringing expertise to Aqualung to support advancing of ALT-100 mAb as a novel therapeutic for inflammatory and fibrotic diseases (ARDS, radiation-induced lung fibrosis, pulmonary arterial hypertension)

Continue reading

C-Path Integrates European Offices to Optimize Global Operations and Collaborative Partnerships

AMSTERDAM and TUCSON, Ariz., July 18, 2023 — Critical Path Institute (C-Path) announced today the completion of the integration of C-Path Ltd. in Dublin, Ireland, into the C-Path nonprofit in Amsterdam, Netherlands. This integration will enable C-Path to increase its activity in Europe and broaden its global operations. C-Path operates in Europe as a nonprofit organisation that builds consensus among its stakeholders from around the world to improve public health. The organisation shares expertise, data, risks and costs to move regulatory science forward.Continue reading